Health Care·Life Sciences Tools & Services·$6.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.12 | N/A | -11.11% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.12 | N/A | -11.11% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management remains focused on strategic initiatives. They acknowledged the EPS miss but emphasized their commitment to future growth.
Management highlighted ongoing investments in product development.
They expressed confidence in long-term growth despite missing EPS expectations.
Repligen's earnings report shows a slight miss on EPS, which may raise concerns among investors. However, the stock reacted positively, increasing by 0.82%. This suggests that investors are still optimistic about the company's long-term prospects despite the EPS miss.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SYSCO CORP
May 2, 2016